Pricing

Industry working group identifies the value characteristics that may, collectively, become part of a higher-level, shared approach to valuing pharmaceutical treatments.

Rick Kelly and Nisha Desai review the proposals in the Pharmaceutical Drug Pricing Reduction Act (PDPRA) with the greatest potential impact.

The impacts of disruptive curative therapies and advances in the future of health will be profound. To be best positioned for success, healthcare systems under continuous cost pressure must address three key areas, writes Thomas Unger.

Leela Barham talks to Sir David Haslam, the outgoing Chair of UK’s National Institute for Health and Care Excellence (NICE), about the highs and lows of his six-year tenure at the organization.

The decision to eradicate pharma rebates and prompt direct discounts for federal beneficiaries could, if passed, upend the market-what are the critical questions for new products?

While there are challenges at every turn, the promise of outcomes-based contracting is a level of care for patients that might otherwise not be possible, while striking the right balance of benefits and risks for all parties involved, writes Melonie Warfel.

Its use, new data shows, could boost the economic benefit profile of more “common” drugs-and better inform HTA and payer decision-making.

In the second in a series of articles summarizing efforts to put each of the “American Patients First” blueprint's four strategies into action, Rick Kelly and Nisha Desai focus on “Better Negotiation”.

Cell and gene therapies in crosshairs of pricing focus, prompting stepped-up proposals on ways to finance these products.

A rule to eradicate drug rebates and prompt direct discounts for federal beneficiaries raises challenging questions for drug manufacturers and other stakeholders.

Ed Schoonveld reviews the key topics discussed at the World Health Organization's second Fair Pricing Forum, held in Johannesburg, South Africa last month.

The UK has had in place what amount to two pricing schemes for branded medicines for years. But with major changes to both schemes set out in 2018, it’s now a new tale of two pricing schemes. Leela Barham reports.

The benefits and challenges of outcomes-based contracting.

Among the new acronyms watch is UPI, or unjustified price increase, recently coined by ICER as part of its new workstream to explore price increases for both branded and generic drugs in the US.

How real-world evidence creates shared value for stakeholders across the healthcare spectrum.

An understanding of copay accumulator and maximizer benefit design programs.

While the increasing importance of real-world evidence (RWE) is widely acknowledged, the dramatic shift required by pharma to embed meaningful and holistic benefits from this capability is still a work in progress.

Bruno Delagneau reviews the current landscape for price-setting in the US and suggests that it’s time for pharma to change their practices.

The U.S. Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) are commitment to support value-based purchasing (VBP) of prescription drugs in Medicaid, despite headlines of CMS’s rejection of a Massachusetts request to make changes in its Medicaid prescription drug benefit.

Charting the course that has led to payer vertical integration and what it may mean for pharma manufacturers.

Practitioners in the field of HEOR training and education outline how the best courses are responding to advancing industry needs.

Executives from diagnostics, payer, pharma, and patient care companies converge to share the inside scoop on outcomes-based contracting.

The biopharma industry should embrace the developments about value assessment in the US and take a leading role in defining and demonstrating what can be considered credible and relevant cost-effectiveness studies, write Ross Maclean and Jeroen Jansen.

Amid contrasting views on the success of the now well-established system of outcomes-based agreements in Italy, further demands on global healthcare budgets will likely point to their adoption on a wider scale